Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 19/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 12/20 | 0.65 |
| ▸ | ABCC1 | P33527 | 7/20 | 0.55 |
| ▸ | LATS1 | O95835 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14320369 | 0.91 | ABCG2 (0.62) | ABCG2ABCB1ABCC1 | |
| SCHEMBL14320419 | 0.90 | ABCG2 (0.68) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL14321014 | 0.89 | ABCG2 (0.57) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL14321350 | 0.89 | ABCG2 (0.65) | ABCG2ABCB1ABCC1LATS1MEN1 | |
| SCHEMBL14320351 | 0.86 | ABCG2 (0.49) | ABCG2ABCB1ABCC1 | |
| SCHEMBL14320373 | 0.86 | ABCG2 (0.54) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL14321059 | 0.86 | ABCG2 (0.63) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL14320361 | 0.85 | ABCG2 (0.53) | ABCG2ABCB1ABCC1 | |
| SCHEMBL14320814 | 0.85 | ABCG2 (0.51) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL15653392 | 0.85 | ABCG2 (0.55) | ABCG2ABCB1ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | claimed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | claimed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | claimed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | ABCG2 3810/4885ABCB1 4019/4885ABCC1 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.